TY - JOUR
T1 - Potentially curable pancreatic adenocarcinoma
T2 - ASCO clinical practice guideline update
AU - Khorana, Alok A.
AU - McKernin, Shannon E.
AU - Berlin, Jordan
AU - Hong, Theodore S.
AU - Maitra, Anirban
AU - Moravek, Cassadie
AU - Mumber, Matthew
AU - Schulick, Richard
AU - Zeh, Herbert J.
AU - Katz, Matthew H.G.
N1 - Publisher Copyright:
© 2019 by American Society of Clinical Oncology
PY - 2019/8/10
Y1 - 2019/8/10
N2 - PURPOSE The purpose of this guideline update is to incorporate recently reported practice-changing evidence into ASCO’s recommendations on potentially curable pancreatic adenocarcinoma. METHODS ASCO convened an Expert Panel to evaluate data from PRODIGE 24/CCTG PA.6, a phase III, multicenter, randomized clinical trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) versus gemcitabine alone, presented at the 2018 ASCO Annual Meeting. In addition, PubMed was searched for additional papers that may influence the existing recommendations. RECOMMENDATIONS The Expert Panel only updated Recommendation 4.1 as a result of the practice-changing data. Recommendation 4.1 states that all patients with resected pancreatic adenocarcinoma who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The modified combination regimen of 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFIRINOX; oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2 D1, and 5-fluorouracil 2.4 g/m2 over 46 hours every 14 days for 12 cycles) is now preferred in the absence of concerns for toxicity or tolerance; alternatively, doublet therapy with gemcitabine and capecitabine or monotherapy with gemcitabine alone or fluorouracil plus folinic acid alone can be offered.
AB - PURPOSE The purpose of this guideline update is to incorporate recently reported practice-changing evidence into ASCO’s recommendations on potentially curable pancreatic adenocarcinoma. METHODS ASCO convened an Expert Panel to evaluate data from PRODIGE 24/CCTG PA.6, a phase III, multicenter, randomized clinical trial of postoperative leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) versus gemcitabine alone, presented at the 2018 ASCO Annual Meeting. In addition, PubMed was searched for additional papers that may influence the existing recommendations. RECOMMENDATIONS The Expert Panel only updated Recommendation 4.1 as a result of the practice-changing data. Recommendation 4.1 states that all patients with resected pancreatic adenocarcinoma who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications. The modified combination regimen of 5-fluorouracil, oxaliplatin, and irinotecan (mFOLFIRINOX; oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2 D1, and 5-fluorouracil 2.4 g/m2 over 46 hours every 14 days for 12 cycles) is now preferred in the absence of concerns for toxicity or tolerance; alternatively, doublet therapy with gemcitabine and capecitabine or monotherapy with gemcitabine alone or fluorouracil plus folinic acid alone can be offered.
UR - http://www.scopus.com/inward/record.url?scp=85070783487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070783487&partnerID=8YFLogxK
U2 - 10.1200/JCO.19.00946
DO - 10.1200/JCO.19.00946
M3 - Article
C2 - 31180816
AN - SCOPUS:85070783487
SN - 0732-183X
VL - 37
SP - 2082
EP - 2088
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 23
ER -